VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | Pacritinib moves foward in MF: PAC2013 and PACIFICA

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the use of pacritinib, an oral JAK2/IRAK1 inhibitor, compared with other therapies in myelofibrosis (MF), which has an upcoming phase 3 trial – PACIFICA. He also highlights the PAC2013 dose-finding study of pacritinib in patients with MF (NCT03165734). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter